$1250 | Single User
$1800 | Site License
$2500 | Global License

Non-Hodgkin Lymphoma Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020
[Lowest Price Guaranteed: $1,250]

Published by Gervano R A: 14 Aug 2019 | 270532 | In Stock
Related Topics: Drug , Hodgkin Lymphoma , Lymphoma

Introduction

GervanoRA’s Pipeline Drug Analytics Report "Non-Hodgkin Lymphoma Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020" provides a detailed overview on Non-Hodgkin Lymphoma Competitive Space. Report provides deep insights on pipeline analytics outlook, drivers, restraints and unmet needs of Non-Hodgkin Lymphoma pipeline drugs, Pipeline Analytics, Epidemiological Studies, Deals Analytics, Patent Analytics of Pipeline Drugs, Pipeline Drug Descriptions and Development Milestones, Clinical Trial Analytics, Competitive Landscape and Opportunity Assessments and Emerging Company Profiles.

Pipeline Analytics Outlook:

Report summarize the comparative snapshots of all pipeline drugs as per the segments like stages of development, Geography, Route of Administration, Drug Class, Mechanism of Action, molecule type, target receptors and company types.

Drivers, Restrains, Unmet Needs and Opportunities:

Report offers and provides a deep knowledge on the drivers, restraints and unmet needs and the opportunities derived upon a far-reaching study on the market trends and underlying factors affecting Non-Hodgkin Lymphoma landscape.

Pipeline Analytics:

The section covers all the molecules (drug candidates) in different stages of development (Discovery, Pre-clinical, Phase 1, Phase 2, Phase 3 and Pre-registration). It also offers information about the terminated and discontinued molecules. Analytics have been provided by Geography (covers major regions like the US, EU, Asia); by Route of Administration, by Drug Class and by Mechanism of Action. Report explains pipeline analytics by molecule type, target receptor and pipeline analytics by company type. Report also covers pipeline analytics by Universities and Institutes.

Epidemiological Studies:

Our Senior Analysts for conducting Epidemiological Studies uses expertise and proprietary tools to understand the prevailing factors affecting the Disease population. Based on demographics, prevalent factors, incidence rate trends and many other geographical factors, Senior Analysts predicts the future numbers of the affected population over the forecast period, even suggesting the preventative measures.

Deals Analytics:

The report bestows explicit information about the collaborations and partnering activities and trend in Non-Hodgkin Lymphoma landscape, including details about different deals types like Mergers and Acquisitions, Licensing deals, Partnering deals, Collaboration Agreements, Series Financings, Grants and Fundings, etc occurring between 2010-2020.

Patent Analytics of Pipeline Drugs:

The section even contains a thorough analysis on the intellectual property pertaining to Non-Hodgkin Lymphoma pipeline drugs. Profound analytics have been provided related to the patent issuance and applications, patent expiries, patent extensions, etc to gain a complete knowledge on the new market entries filling up the gaps due to the patent expiries.

Pipeline Drug Descriptions and Development Milestones:

Report provides detailed pipeline drugs descriptions covering all key aspects of the pipeline drugs like intended indications, mechanism of action, route of administration and role in pathophysiological conditions. Report even covers all development milestones of the pipeline drugs right from the early research and development to current stage of development.

Clinical Trial Analytics:

The report is inclusive of all the updated clinical trials information, providing details related to the completed clinical trials, ongoing clinical trials, planned clinical trials, even including complete analytics based on sponsors (companies, universities and institutes) involved in the development of Non-Hodgkin Lymphoma Therapeutics.

Competitive Landscape and Opportunity Assessments:

The report is an absolute package covering all the companies - Established and emerging companies (Clinical-stage companies, pre-clinical stage companies, startups) actively involved in the R&D of new therapeutics for the treatment of Non-Hodgkin Lymphoma. Report provided opportunity assessments by performing a competitive and comparative analysis on the top 20 Emerging companies in the competitive space.

Emerging Company Profiles:

Report features company profiles with data concentrated on: Partnering activities and patent analysis of the company, R&D efforts and advancements, Comparison of internal investment and external funding, Achievements of special regulatory allowances and Outline of in-licensing/out licensing opportunities.

Table of Contents
for Non-Hodgkin Lymphoma Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020

  • CHAPTER 01: INTRODUCTION

    1.1. REPORT DESCRIPTION

    1.2. METHODOLOGY

    1.3. ABOUT US: GERVANORA DATA SERVICES

    CHAPTER 02: EXECUTIVE SUMMARY

    2.1. REPORT SUMMARY

    2.2. KEY EVENTS IN THE NON-HODGKIN LYMPHOMA COMPETITIVE SPACE

    2.3. REPORT MAJOR FINDINGS

    2.3.1. DRIVERS

    2.3.2. RESTRAINTS

    2.3.3. OPPORTUNITIES

    CHAPTER 03: PIPELINE ANALYTICS OUTLOOK

    3.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS

    3.1.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY STAGE OF DEVELOPMENT

    3.1.2. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY GEOGRAPHY

    3.1.3. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY ROUTE OF ADMINISTRATION

    3.1.4. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY DRUG CLASS

    3.1.5. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MECHANISM OF ACTION

    3.1.6. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULE TYPE

    3.1.7. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULAR TARGET

    3.1.8. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY COMPANY TYPE

    3.2. UNMET NEEDS AND MARKET DEMANDS

    3.2.1. UNMET NEEDS AND MARKET DEMANDS FOR NEWER THERAPIES

    3.2.2. UNMET NEEDS AND MARKET DEMANDS BY ROUTE OF ADMINISTRATION

    3.2.3. UNMET NEEDS AND MARKET DEMANDS BY GEOGRAPHY

    3.3 MARKET DYNAMICS OF NON-HODGKIN LYMPHOMA COMPETITIVE LANDSCAPE

    CHAPTER 04: DISEASE OVERVIEW AND EPIDEMIOLOGICAL STUDIES

    4.1. DISEASE DEFINITION AND SYMPTOMS

    4.2. DISEASE CAUSE AND PATHOPHYSIOLOGY

    4.3. DISEASE DIAGNOSIS

    4.4. TREATMENT ALGORITHM AND GUIDELINES

    4.5. EPIDEMIOLOGY STUDIES

    3.5.1. GLOBAL AND HISTORICAL TRENDS

    4.6. EPIDEMIOLOGY FORECAST

    4.6.1. FORECAST METHODOLOGY AND ASSUMPTIONS

    4.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

    CHAPTER 05: DEALS (M&A) ANALYTICS OF NON-HODGKIN LYMPHOMA COMPETITIVE LANDSCAPE

    4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)

    4.1.1 DEALS ANALYTICS BY DEAL TYPE

    4.1.1.1. COLLABORATION DEALS

    4.1.1.2. LICENSING DEALS

    4.1.1.3. FINANCING DEALS

    4.1.2 DEALS ANALYTICS BY ANNUAL FREQUENCY

    4.1.3 DEALS ANALYTICS BY ACTIVE PLAYER

    CHAPTER 06: PATENT ANALYTICS OF NON-HODGKIN LYMPHOMA PIPELINE DRUGS

    6.1. PATENT ANALYTICS BY GEOGRAPY

    6.2. PATENT ANALYTICS BY PATENT EXPIRY

    6.3. PATET ANALYTICS BY SPECIAL ALLOWANCES AND TERM EXTENSIONS

    CHAPTER 07: PIPELINE DRUGS ANALYTICS OF NON-HODGKIN LYMPHOMA

    7.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT

    5.1.1. PRE-REGISTRATION PIPELINE DRUGS

    5.1.2. PHASE III PIPELINE DRUGS

    5.1.3. PHASE II PIPELINE DRUGS

    5.1.4. PHASE I/II PIPELINE DRUGS

    5.1.5. PHASE I PIPELINE DRUGS

    5.1.6. PRE-CLINICAL PIPELINE DRUGS

    5.1.7. EARLY R&D PIPELINE DRUGS

    5.1.8. INACTIVE AND DISCONTINOUED PIPELINE DRUGS

    5.2. PIPELINE DRUGS ANALYTICS BY GEOGRAPHY

    5.3. PIPELINE DRUGS ANALYTICS BY ROUTE OF ADMINISTRATION

    5.4. PIPELINE DRUGS ANALYTICS BY DRUG CLASS

    5.5. PIPELINE DRUGS ANALYTICS BY MECHANISM OF ACTION

    5.6. PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE

    5.7. PIPELINE DRUGS ANALYTICS BY TARGET RECEPTORS

    5.8. PIPELINE DRUGS ANALYTICS BY COMPANY TYPE

    CHAPTER 08: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    6.1. PRE-REGISTRATION PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    6.2. PHASE III PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    6.3. PHASE II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    6.4. PHASE I/II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    6.5. PHASE I PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    CHAPTER 09: ESTIMATED APPROVAL TIMELINES OF NON-HODGKIN LYMPHOMA PIPELINE DRUGS

    7.1. METHODOLOGY

    7.2. ESTIMATED APPROVAL TIMELINES US & EX-US

    CHAPTER 10: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

    8.1. EXTERNAL DEPENDENCIES

    8.1.1. BUSINESS R&D - INTERNAL INVESTMENT AND EXTERNAL FUNDING

    8.2. PIPELINE PORTFOLIO

    8.3. EXPECTED MARKET ENTRIES

    8.4. PATENTS AND EXCLUSIVITY

    8.5. MARKET DYNAMICS AND PARTNERING

    8.6. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES

    8.7. COMPANY DEVELOPMENTS

    CHAPTER 11: CURRENT AND FUTURE COMPETITIVE LANDSCAPE

    9.1. EMERGING COMPANIES

    9.1.1 EMERGING COMPANY PROFILES

List Of Tables
in Non-Hodgkin Lymphoma Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020

LIST OF TABLES

• TABLE 01: NON-HODGKIN LYMPHOMA REPORT HIGHLIGHTS IN NUMERICALS

• TABLE 02: COLLABORATION DEALS IN NON-HODGKIN LYMPHOMA THERAPEUTIC AREA

• TABLE 03: LICENSING DEALS IN NON-HODGKIN LYMPHOMA THERAPEUTIC AREA

• TABLE 04: FINANCING DEALS IN NON-HODGKIN LYMPHOMA THERAPEUTIC AREA

• TABLE 5: NON-HODGKIN LYMPHOMA PHASE III PIPELINE MOLECULES

• TABLE 6: NON-HODGKIN LYMPHOMA PHASE II PIPELINE MOLECULES

• TABLE 7: NON-HODGKIN LYMPHOMA PHASE I/II PIPELINE MOLECULES

• TABLE 8: NON-HODGKIN LYMPHOMA PHASE I PIPELINE MOLECULES

• TABLE 9: PRECLINICAL STAGE DRUG CANDIDATES FOR NON-HODGKIN LYMPHOMA

• TABLE 10: LIST OF PIPELINE MOLECULES OF PARENTERAL ROUTE OF ADMINISTRATION

• TABLE 11: LIST OF PIPELINE MOLECULES OF ORAL ROUTE OF ADMINISTRATION

• (Remaining Tables can be seen in detailed Report)

List Of Figures, Charts and Diagrams
in Non-Hodgkin Lymphoma Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020

LIST OF FIGURES

• FIGURE 01: KEY EVENTS IN THE NON-HODGKIN LYMPHOMA COMPETITIVE SPACE

• FIGURE 02: NON-HODGKIN LYMPHOMA DEAL ANALYTICS BY DEAL TYPE

• FIGURE 03: NON-HODGKIN LYMPHOMA DEAL ANALYTICS BY DEAL FREQUENCY

• FIGURE 04: PIPELINE MOLECULES - CLINICAL VS PRECLINICAL & EARLY R&D

• FIGURE 05: TOTAL PIPELINE MOLECULES VS STAGE OF DEVELOPMENT

• FIGURE 06: NON-HODGKIN LYMPHOMA DRUGS PIPELINE ANALYTICS BY ROA

• FIGURE 07: NON-HODGKIN LYMPHOMA DRUGS PIPELINE ANALYTICS BY PARENTERAL ROA

• FIGURE 08: PARENTERAL DRUGS PIPELINE ANALYTICS BY HSD

• FIGURE 09: ORAL DRUGS PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT

• FIGURE 10: TOTAL PIPELINE MOLECULES V/S DRUG CLASSES

• FIGURE 11: PIPELINE DRUG CLASS ANALYTICS BY STAGE OF DEVELOPMENT

• FIGURE 12: NON-HODGKIN LYMPHOMA PIPELINE DRUGS BIOLOGICALS VS SMALL MOLECULES

• FIGURE 13: NON-HODGKIN LYMPHOMA PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE VS STAGE OF DEVELOPMENT

• FIGURE 14: NON-HODGKIN LYMPHOMA COMPANIES (NUMBER, PERCENT SHARE)

• FIGURE 15: GEOGRAPHICAL CATEGORIZATION OF COMPANIES WORKING ON NON-HODGKIN LYMPHOMA

• (Remaining Figures can be seen in detailed Report)

Additional Details

Publisher

Gervano R A

Publisher Information

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports, and consulting services, based in Goa. It provides Market Research And Analysis Services to its clients globally.



GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.



At GervanoRA Data Services, we’re playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations to garner valuable key insights.

Reference

270532 | GERPH513

Number of Pages

187

Report Format

PDF

Gervano R A Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Market Access for Orphan Drugs: assessing the global landscape
IntroductionTheir development costs can be high and the market is relative small, yet orphan drugs r...
01 Dec 2013 by FirstWord Pharma USD $695 More Info
Physician Views: What opportunity for Novo Nordisk's Victoza in obesity?
Scope Analysts have notably mixed opinions on the commercial opportunity, but one of the more intrig...
01 Nov 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Life beyond statins – what opportunity for PCSK9 inhibitors?
ScopeWith Sanofi and Regeneron Pharmaceuticals set to unveil the first Phase III data for their expe...
01 Oct 2013 by FirstWord Pharma USD $695 More Info
Physician Views: The great generic Advair opportunity – a physician perspective
ScopeAs illustrated here – see FirstWord Lists: Leading respiratory drugs 2012 and 2018 – the respir...
01 Oct 2013 by FirstWord Pharma USD $695 More Info
Physician Views: What opportunity for Gilead Sciences' hepatitis C therapy sofosbuvir before interferon-sparing regiments reach the market?
ScopeOne of the key features of the hepatitis C treatment landscape over the past year to 18 months ...
01 Oct 2013 by FirstWord Pharma USD $695 More Info
Charting the Biosimilar and Biobetter Development Pipeline (2013)
IntroductionIf you need to understand the important biosimilar and biobetter drug developments world...
01 Jul 2013 by FirstWord Pharma USD $2,195 More Info
Effective sales and marketing strategies for drugs with companion diagnostics
IntroductionTo fully exploit the commercial advantages of companion diagnostics, Pharma companies ne...
01 May 2013 by FirstWord Pharma USD $695 More Info
Physician Views: What opportunity beyond the anti-TNFs in rheumatoid arthritis?
Scope Last week, FirstWord identified Bayer and Johnson & Johnson's anticoagulant Xarelto as the ind...
18 Mar 2013 by FirstWord Pharma USD $695 More Info
Charting the Biosimilar and Biobetter Development Pipeline
IntroductionBiosimilar development has failed to meet expectations in recent years, but that is set ...
01 Sep 2012 by FirstWord Pharma USD $2,195 More Info
Effective Sales and Marketing Strategies for Orphan Drugs
IntroductionThe real potential for orphan drug pharma marketingWith drug pipelines moving from essen...
01 Jun 2012 by FirstWord Pharma USD $695 More Info

This report is published by Gervano R A

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports, and consulting services, based in Goa. It provides Market Research And Analysis Services to its clients globally.

GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.

At GervanoRA Data Services, we’re playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations to garner valuable key insights.

Download Free Report Summary PDF

Non-Hodgkin Lymphoma Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...